Log In
Print
BCIQ
Print
Print this Print this
 

NP-1998 (formerly NGX-1998)

  Manage Alerts
Collapse Summary General Information
Company NeurogesX Inc.
DescriptionTopical liquid formulation of synthetic capsaicinin
Molecular Target Transient receptor potential vanilloid 1 (TRPV1) (VR1)
Mechanism of ActionTransient receptor potential vanilloid 1 (TRPV1) (VR1) agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat neuropathic pain; Treat peripheral neuropathic pain; Treat postherpetic neuralgia (PHN)
Regulatory Designation

Partner

Acorda Therapeutics Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today